Skip to main content
Premium Trial:

Request an Annual Quote

Intradigm, Europroteome Pen siRNA Cancer Collaboration

NEW YORK, July 17 - Intradigm will apply its small interfering RNA delivery technology to one of Europroteome's cancer targets, the companies said today.

Intradigm has developed a set of delivery systems for siRNA duplexes that can be delivered into pathological tissues, including human xenograft tumor models. The company said it has already used the technology to validate cancer targets.

 

Europroteome, meantime, has identified and validated its own cancer targets based on its proteomic and human-cell-based studies. The company said that using Intradigm's method to further validate these targets in tumor models "is expected to provide important information" related to its pre-clinical development program for its cancer targets.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.